Late vascular response at the edges of sirolimus analogous-eluting stents in diabetic patients: An intravascular ultrasound study

Catheterization and Cardiovascular Interventions

Volumn 70, Issue 4, 2007, Pages 498-503

  Lasave, Leandro I ^a   Abizaid, Alexandre A C ^a,b   Costa Jr , José De Ribamar ^a   Tanajura, Luiz F ^a   Feres, Fausto ^a   Abizaid, Andrea S ^a   Siqueira, Dimytri ^a   Staico, Rodolfo ^a   Sousa, Amanda G R M ^a   Sousa, J Eduardo ^a  

^a INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^b NONE   (Brazil)

Author keywords

Diabetes mellitus; Drug eluting stents; Intravascular ultrasound; Vessel remodeling

Indexed keywords

BIOLIMUS; CYPHER; RAPAMYCIN; UNCLASSIFIED DRUG; ZOMAXX; ZOTAROLIMUS;

ADULT; AGED; ARTICLE; BLOOD VESSEL REACTIVITY; CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; RESTENOSIS; TREATMENT RESPONSE;

AGED; CARDIOVASCULAR AGENTS; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; DIABETIC ANGIOPATHIES; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTHESIS DESIGN; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 35349020574     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21139     Document Type: Article

References (23)

1. Waksman R, Raizner AE, Yeung AC, Lansky AJ, Vandertie L. Use of localised intracoronary β radiation in treatment of in-stent restenosis: The INHIBIT randomized controlled trial. Lancet 2002;359:551-557.
2. Leon MB, Teirstein PS, Moses JW, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001;344:250-256.
3. 32P radioactive β-emitting stents. Circulation 2000;101:2454-2457.
4. 32P radioactive stent. Circulation 2000;101:3-7.
5. Morice MC, Serruys PW, Sousa JE, et al. Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with the novo native coronary artery lesions. N Engl J Med 2002;346:1773-1780.
6. Serruys P, Degertekin M, Tanabe K, et al. Intravascular ultrasound findings in the multicenter, randomized, double blind RAVEL trial. Circulation 2002;106:798-803.
7. Degertekin M, Serruys PW, Foley DP, et al. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: Long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation 2002;106:1610-1613.
8. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-195.
9. DuVall M, Ji Q, Clifford A, et al. ABT-578 elution profile and arterial penetration using the ZoMaxx drug-eluting stent. Am J Cardiol 2004;94:223E (abstract).
10. Meredith IT, Ormiston J, Whitbourn R, et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in the novo native coronary artery lesions: ENDEAVOR I Trial. Eurointervention 2005;1:157-164.
11. Serruys PW, Kutryk M Ong A. Drug therapy: Coronary-artery stents. N Engl J Med 2006;354:483-495.
12. Grube E, Hauptmann KE, Buellesfeld L, Lim V, Abizaid A. Six-month results of a randomized study to evaluate safety and efficacy of a Biolimus A9 eluting stent with a biodegradable polymer coating. Eurointervention 2005;1:53-57.
13. Lasave LI, Abizaid A, Feres F, et al. Comparative study between the new zotarolimus-eluting stent (ZoMaxx) and the bare TriMaxx stent. Late volumetric analysis with intravascular ultrasound. Am J Cardiol 2006;98:129M (abstract).
14. Mintz G, Nissen SE, Anderson W, et al. American College of Cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology task force on clinical expert consensus documents. J Am Coll Cardiol 2001;37:1478-1492.
15. Costa JR, Mintz G, Carlier S, et al. Frequency and determinants of black holes in sirolimus-eluting stent restenosis. J Invasive Cardiol 2006;18:348-352.
16. Wardeh AJ, Albiero R, Kay IP, et al. Angiographical follow-up after radioactive "Cold Ends" stent implantation: A multicenter trial. Circulation 2002;105:550-553.
17. Albiero R, Adamian M, Kobayashi N, et al. Short- and intermediate-term results of 32P radioactive β-emitting stent implantation in patients with coronary artery disease: The Milan dose-response study. Circulation 2000;101:18-26.
18. Lasave LI, Abizaid AS, Abizaid A, et al. Late volumetric analysis of in-stent neointimal hyperplasia among three rapamycin-derivated eluting stents. An intravascular ultrasound study. Am J Cardiol 2006;98:130M (abstract).
19. Jimenez-Quevedo P, Sabate M, Angiolillo DJ, et al. Vascular effects of sirolimus-eluting versus bare-metal stents in diabetic patients: Three-dimensional ultrasound results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial. J Am Coll Cardiol 2006;47:2172-2179.
20. Serruys PW, Degertekin M, Tanabe K, et al. Vascular responses at proximal and distal edges of paclitaxel-eluting stents. Serial intravascular ultrasound analysis from the TAXUS II trial. Circulation 2004;109:627-633.
21. Weissman NJ, Wilensky RL, Tanguay JF, et al. Extent and distribution of in-stent intimal hyperplasia and edge effect in a non-radiation stent population. Am J Cardiol 2001;88:248-252.
22. Reddy H, Koshy S, Wasson S, et al. Adaptive-outward and maladaptive-inward arterial remodeling measured by intravascular ultrasound in hyperhomocysteinemia and diabetes. J Cardiovasc Pharmacol Ther 2006;11:65-76.
23. Mintz GS, Shah VM Weissman NJ. Regional remodeling as the cause of late stent malapposition. Circulation 2003;107:2660-2663.